2021 American Transplant Congress
Outcomes of DCD Allografts in Liver Transplant Recipients with HCC
*Purpose: Early studies demonstrated inferior survival for liver transplant (LT) recipients with hepatocellular carcinoma (HCC) who received allografts from donation after cardiac death (DCD) donors…2021 American Transplant Congress
Adjuvant Immunotherapy for Liver Transplant Recipients with Hepatocellular Carcinoma Using Donor Liver-derived Natural Killer Cells
1Hiroshima University, Hiroshima, Japan, 2University of Miami, Miami, FL
*Purpose: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is an indication for liver transplantation (LT). Immunosuppressive regimens currently used after…2021 American Transplant Congress
Waitlist Outcomes for Exception Candidates Following the Implementation of MMaT/250 Score
1Johns Hopkins Medical Institutions, Baltimore, MD, 2Temple University, Philadelphia, PA
*Purpose: Starting in May 2019, exception points were allocated based on DSA-level median-MELD-at-transplant (MMaT/DSA). In February 2020, the exception point system was further modified based…2021 American Transplant Congress
T Cell Repertoire Diversity in HCV-Associated Hepatocellular Carcinoma Patients Waitlisted for Liver Transplantation and Receiving Liver-Directed Therapy
Ochsner Health, New Orleans, LA
*Purpose: T cell receptor (TCR) sequencing in hepatocellular carcinoma (HCC) patients revealed a diverse TCR repertoire in hepatitis B-associated HCC-infiltrating T cells. In this study,…2021 American Transplant Congress
State-level Trend in the Prevalence of Non-alcoholic Steatohepatitis for Liver Transplant Candidates in the United States, 2001-2017
1Washington University School of Medicine, Saint Louis, MO, 2Northwestern University, Chicago, IL
*Purpose: As variation in the prevalence of obesity across states continues to grow, the prevalence of nonalcoholic steatohepatitis (NASH) is also rising. However, little is…2021 American Transplant Congress
Waitlist Outcomes for Patients with Hepatocellular Carcinoma Following the 2019 Exception Policy Change
*Purpose: We aim to compare waitlist (WL) outcomes for HCC patients after the implementation of the most recent UNOS exception policy change on 5/1/2019.*Methods: All…2021 American Transplant Congress
The Tumor-suppressor Signaling of the α1-na/k-atpase- Cav-1-src Complex at the Caveola in Nash Related Hepatocellular Carcinoma
*Purpose: Hepatocellular Carcinoma (HCC) is the 2nd and fastest-growing cause of cancer related mortality worldwide, mainly from the metabolic cellular disturbances promoted by the epidemic…2021 American Transplant Congress
Given the Potential Impact on Liver Transplant Selection, Revisiting the Current Standard of Diagnosis of Hepatocellular Carcinoma
*Purpose: The current standard of diagnosis of hepatocellular carcinoma (HCC) relies on non-invasive radiographic methods, namely computerized tomography (CT) and/or magnetic resonance imaging (MRI). However,…2021 American Transplant Congress
Effects of TIPS on Transplant Outcomes for HCC
*Purpose: The purpose of this study is to examine effects of TIPS placement on response to locoregional therapy (LRT) and clinical outcomes after liver transplantation…2021 American Transplant Congress
Immunotherapy of Dc-cik Cells in Patient with Hepatocellular Carcinoma Recurrence Following Liver Transplantation
China Medical University Hospital, Taichung, Taiwan
*Purpose: Dendritic cells (DCs) and cytokine-induced killer (CIK) cells, components of anti-cancer therapy, have shown clinical benefits and potential to overcome chemotherapeutic resistance in some…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 23
- Next Page »